Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Esketamine vs racemic ketamine dosing cannot be converted with one fixed ratio for depression treatment. Esketamine is the S-enantiomer in FDA-approved Spravato nasal spray, while racemic ketamine contains equal S- and R-ketamine and is prescribed off-label for psychiatric uses. Route, indication, monitoring, medical history, and response over time matter more than a simple milligram comparison.
For readers comparing options, the practical difference is this: Spravato has a labeled intranasal schedule and supervised administration requirements, while racemic ketamine dosing varies by route and clinician protocol. A prescriber should determine whether either approach fits your diagnosis, medications, blood pressure history, and follow-up plan.
Quick Answer
Esketamine is dosed as a fixed intranasal product under a supervised program, commonly 56 mg or 84 mg for adults with treatment-resistant depression. Racemic ketamine is not FDA-approved for depression, and its psychiatric dosing protocols vary, including a commonly studied 0.5 mg/kg intravenous infusion over 40 minutes. Do not use anesthetic potency estimates to self-convert one treatment into the other.
What each medication contains
Ketamine is a chiral medication with two mirror-image forms, S-ketamine and R-ketamine. Esketamine is S-ketamine alone. Racemic ketamine is a 50:50 mixture of S-ketamine and R-ketamine.
Spravato is the brand name for intranasal esketamine. The MedlinePlus esketamine drug record states that it is used with an oral antidepressant for adults with treatment-resistant depression and is given in a healthcare setting. Racemic ketamine is an older generic anesthetic medication; psychiatric use is off-label, meaning the FDA has not approved a specific racemic ketamine product for depression.
That distinction affects access and administration. It does not establish that one option will work better for an individual person.
Why a direct dose conversion is unreliable
Esketamine has greater NMDA receptor affinity than R-ketamine, and anesthetic literature has often described S-ketamine as more potent than racemic ketamine on a milligram basis. That pharmacology does not create a validated depression-treatment conversion between 56 mg or 84 mg intranasal esketamine and an intravenous, oral, or sublingual racemic ketamine regimen.
The routes produce different absorption and peak concentrations. Intravenous dosing places the full dose directly into circulation. Intranasal dosing is absorbed through nasal tissue. Oral and sublingual products have their own absorption patterns and first-pass metabolism. A number printed on a treatment plan is therefore only one part of the dosing context.
Research also has not settled whether the R-ketamine component, its metabolites, or non-NMDA pathways materially change comparative antidepressant effects in people. Preclinical findings can guide research questions, but they are not a reason to adjust a prescribed dose independently.
A systematic review and meta-analysis indexed by PubMed examined comparative efficacy evidence, but differences in route, study design, populations, and treatment schedules limit simple head-to-head conclusions.
Compare low-dose options
Review routes, dosing discussions, and alternatives before speaking with a clinician.
Compare optionsKey Takeaway
A dose comparison is most useful when it includes formulation, route, treatment goal, monitoring, timing, and symptom response. Milligrams alone leave out the information that makes a regimen clinically meaningful.
What the approved esketamine schedule says
For adults with treatment-resistant depression, Spravato labeling uses 56 mg or 84 mg twice a week during the first four weeks. The frequency then decreases during later phases based on the labeled schedule and clinical judgment. According to MedlinePlus, patients must be monitored by a healthcare provider for at least 2 hours after each esketamine dose.
Spravato is available only through a Risk Evaluation and Mitigation Strategy, or REMS, program. The FDA describes this program as requiring administration under direct observation and monitoring because of risks including sedation, dissociation, respiratory depression, abuse and misuse. See the FDA approval announcement for the agency's original description of the treatment and its restrictions.
Fixed-device doses can make the delivered product dose easier to identify, but they do not remove the need to assess blood pressure, sedation, dissociation, transportation home, or whether symptoms are improving between visits.
How racemic ketamine protocols are usually discussed
Intravenous racemic ketamine at 0.5 mg/kg over 40 minutes is a frequently cited research regimen for depression. It is not a universal protocol, and it should not be treated as a self-dosing reference. Clinics may use different routes, frequencies, assessment tools, and follow-up practices.
Oral, sublingual, and compounded formulations deserve particular caution in comparisons. A reported dose such as 50-150 mg does not predict the same blood level or experience as an intravenous infusion. Product formulation, administration technique, timing, concurrent medicines, and metabolism can all affect exposure.
If you are considering a non-intravenous option, review the details in this ketamine troche dosage guide and ask the prescribing clinician how the chosen route changes onset, duration, monitoring, and dose adjustments.
Questions to bring to a dosing discussion
- Which formulation and route are you recommending, and why does it fit my treatment goal?
- What outcome will we track between sessions, and when would the dose or spacing be reviewed?
- Which of my current medicines, alcohol use, blood pressure issues, or cardiovascular history need review first?
- What monitoring will occur during treatment and what symptoms should prompt me to contact the care team?
- How will treatment frequency change after the initial phase, if it is helping?
Safety and follow-up matter as much as the dose
Both esketamine and racemic ketamine can cause short-term dissociation, sedation, increases in blood pressure, nausea, and impaired ability to drive after treatment. The degree and timing may differ by route and person. Your clinician should review contraindications and precautions using the applicable product information and your medical record.
Do not combine ketamine treatment with alcohol or make medication changes on your own. Read about ketamine and alcohol interaction safety risks before treatment, and discuss benzodiazepines, opioids, stimulants, and other prescriptions with the clinician managing your care.
A good follow-up plan records symptoms, side effects, sleep, functioning, blood pressure when requested, and how long any changes last. That record helps distinguish a single difficult treatment day from a pattern that may justify changing the dose, route, or spacing. Our guide to treatment spacing explains why session timing should be reviewed as part of the overall plan.
When esketamine may be easier to evaluate
- It has an FDA-approved intranasal product label for specified depression indications.
- Its device doses and required supervised setting create a defined administration framework.
- Its labeled schedule gives patients and clinicians a shared starting point for treatment frequency.
Questions that still need answers
- A labeled dose does not predict an individual's response or tolerability.
- It requires healthcare-setting administration and post-dose observation.
- Coverage, eligibility, and out-of-pocket responsibility depend on the patient's plan and clinical documentation.
Bottom line
Esketamine and racemic ketamine are related medications, but their depression-treatment doses are not interchangeable. Esketamine offers a labeled intranasal schedule and required observation. Racemic ketamine is used off-label through protocols that must be interpreted in the context of route, monitoring, and the individual's clinical history.
The safest comparison is not “which number of milligrams is stronger?” It is “which formulation, setting, schedule, and follow-up process can a qualified clinician support for my situation?” For more context on side effects and what to record after treatment, see our guide to common ketamine side effects.
Keep Reading Dosing Guides
Review practical guides on dose context, treatment timing, and the questions to discuss with your clinician.
Frequently asked questions
No. They differ in composition, route, absorption, and treatment framework. An intranasal esketamine dose should not be converted to a racemic ketamine dose without the prescribing clinician's guidance.
Coverage varies. Racemic ketamine is not FDA-approved for depression, so coverage for psychiatric use is often limited or unavailable. Contact your insurer and treatment provider for the current details of your plan.
Spravato is subject to a REMS program because of safety risks that include sedation, dissociation, respiratory depression, and abuse and misuse. The product's healthcare-setting requirements include monitoring after administration.
Contact the clinician managing treatment rather than changing the schedule yourself. Symptom timing, side effects, other medications, and safety monitoring all help determine whether a schedule change is appropriate.
Share
Related Reading
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.